

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-53 (canceled).

54 (Previously Amended). A method for antitumor therapy, comprising

administering to a subject in need of such treatment, a therapeutically effective amount of a non-encapsulated chemotherapy drug and an immunostimulating cytokine,

wherein the cytokine is encapsulated in multilamellar liposomes (MLV),

said treatment being characterized in that the subject is administered on non-consecutive days with two or more DOSES of said liposome encapsulated cytokine,

a first dose being administered at least 3 days following administration of said chemotherapeutic drug,

wherein the time between administrations is such that the therapeutic effect of the combined administrations is greater than the sum of the therapeutic effects produced by administration of said chemotherapeutic drug alone and by administration of said immunostimulating cytokine alone.

55 (canceled).

56 (previously presented): The method of claim 54, wherein said cytokine is selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, INF- γ , INF- α , INF- β , G-CSF, and GM-CSF.

57 (canceled).

58 (previously presented): The method of claim 56, wherein said cytokine is IL-2.

59 (canceled).

60 (previously presented): The method of claim 54 wherein the liposomes comprise at least one lipid selected from the group consisting of dimyristoyl phosphatidyl choline (DMPC), dimyristoyl phosphatidyl glycerol (DMPG), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), phosphatidyl choline, phosphatidyl ethanolamine and cholesterol.

61 (canceled).

62 (previously presented): The method of claim 60, wherein said cytokine is encapsulated in liposomes comprising (1) DMPC and (2) at least one additional lipid selected from the group consisting of dimyristoyl phosphatidyl glycerol (DMPG), and 1,2-distearoyl-3-trimethylammonium propane

(DSTAP), said at least one additional lipid being in an amount of up to 50%.

63 (canceled).

64 (previously presented): The method of claim 62, wherein said liposome is composed of DMPC and DMPG.

65 (canceled).

66 (previously presented): The method of claim 64, wherein the liposome comprise DMPC and DMPG in a molar ratio of about 9:1.

67 (canceled).

68 (previously presented): The method of claim 54, wherein said chemotherapeutic drug is selected from the group consisting of a chemotherapeutic anthraquinone, cisplatin, and a topoisomerase I inhibitor.

69 (canceled).

70 (previously presented): The method of claim 68, wherein said chemotherapeutic drug is doxorubicin (adriamycin).

71 (canceled).

72 (currently amended): A method for antitumor therapy, comprising

administering to a subject in need of such treatment, a therapeutically effective amount of a chemotherapeutic drug encapsulated in liposomes and an immunostimulating cytokine encapsulated in MLV,

said treatment being characterized in that the subject is administered on non-consecutive days with two or more doses of said liposome encapsulated cytokine,

a first dose being administered at least 3 days following administration of said liposome encapsulated chemotherapeutic drug,

wherein the time between administration of said liposome encapsulated chemotherapeutic drug and said liposome encapsulated cytokine is such that the combined therapeutic effect of said administrations is greater than a sum of the therapeutic effect produced by administration of the liposome encapsulated chemotherapeutic drug alone ~~and by administration of said liposome encapsulated chemotherapeutic drug alone and~~ by administration of said liposome encapsulated immunostimulating cytokine alone.

73 (canceled).

74 (previously presented): The method of claim 72, wherein said cytokine is selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, INF- γ , INF- α , INF- β , G-CSF, and GM-CSF.

75 (canceled).

76 (previously presented): The method of claim 74, wherein said cytokine is IL-2.

77 (canceled).

78 (previously presented): The method of claim 72 wherein the liposomes encapsulating said immunostimulating cytokine comprise at least one lipid selected from the group consisting DMPC, DMPG, DSTAP, phosphatidyl choline, phosphatidyl ethanolamine and cholesterol.

79 (canceled).

80 (previously presented): The method of claim 78, wherein said cytokine is encapsulated in liposomes comprising (1) DMPC and (2) at least one additional lipid selected from the group consisting of DMPG and DSTAP, said at least one additional lipid being in an amount of up to 50%.

81 (canceled).

82 (previously presented): The method of claim 80, wherein said liposome comprise of DMPC and DMPG.

83 (canceled).

84 (previously presented): The method of claim 82, wherein the liposome DMPC and DMPG are present in a molar ratio of about 9:1.

85 (canceled).

86 (previously presented): The method of claim 72, wherein the liposomes encapsulating said chemotherapeutic drug comprise 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 dalton.

87 (canceled).

88 (previously presented): The method of claim 72, wherein said chemotherapeutic drug is selected from the group consisting of a chemotherapeutic anthraquinone, cisplatin, and a topoisomerase I inhibitor.

89 (canceled).

90 (previously presented): The method of claim 88, wherein said chemotherapeutic drug is doxorubicin (adriamycin).

Appln. No. 09/555,674
Amd. dated August 29, 2003
Reply to Office Action of May 29, 2003

91 (canceled).

92 (previously presented): The method of claim 90,
wherein said chemotherapeutic drug is polyethylene glycol-
coated liposomal doxorubicin.

93 (canceled).